ProShares Ultra NASDAQ Biotechnology
22 hedge funds and large institutions have $8.2M invested in ProShares Ultra NASDAQ Biotechnology in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 4 closing their positions.
114% more call options, than puts
Call options by funds: $2.59M | Put options by funds: $1.21M
39% more capital invested
Capital invested by funds: $5.9M → $8.2M (+$2.3M)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
5% more funds holding
Funds holding: 21 → 22 (+1)
1.87% more ownership
Funds ownership: 7.24% → 9.1% (+1.9%)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IMC Chicago
Chicago,
Illinois
|
+$2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$645K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$417K |
| 4 |
PWM
Palumbo Wealth Management
Great Neck,
New York
|
+$188K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$114K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCWM
Cassaday & Co Wealth Management
Mclean,
Virginia
|
-$1.38M |
| 2 |
JF
Jump Financial
Chicago,
Illinois
|
-$393K |
| 3 |
Vontobel Holding
Zurich,
Switzerland
|
-$324K |
| 4 |
TCBWMS
Texas Capital Bank Wealth Management Services
Dallas,
Texas
|
-$240K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$235K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| – | -$40.7K | -849 | Closed |
|
BIB Hedge Fund Activity: Q4 2023 in Review
22 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q4 2023, worth a combined $8.2M — up 39% from $5.9M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BIB positions and 4 closed out — a net gain of 1 holder — while 5 added to existing stakes and 5 trimmed.
The largest buyer was IMC Chicago, opening a new position worth an estimated $2M. The largest seller was Cassaday & Co Wealth Management, cutting an estimated $1.38M.
- 22 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q4 2023, up from 21 in Q3 2023.
- Funds reported $8.2M of ProShares Ultra NASDAQ Biotechnology stock for Q4 2023, up 39% quarter-over-quarter.
- 5 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q4 2023 and 4 closed out, a net change of +1 holder.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q4 2023 was IMC Chicago, an estimated $2M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q4 2023 was Cassaday & Co Wealth Management, an estimated $1.38M sold.
Based on aggregated 13F filings for Q4 2023.